For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|
| Revenues | 0 | 41 | 42 | 57 |
| Cost of revenue | 0 | 41 | 42 | 48 |
| Gross profit | 0 | 0 | 0 | 9 |
| Research and development expense | 1,643 | 968 | 1,477 | 1,086 |
| General and administrative expense | 1,613 | 1,232 | 1,544 | 1,088 |
| Net expenses related to opko collaboration agreement | 3,256 | 2,200 | 3,021 | 2,174 |
| Operating loss | -3,256 | -2,199 | -3,021 | -2,165 |
| Financial income, net | 56 | 13 | - | 20 |
| Income (loss) from continuing operations before income taxes, noncontrolling interest | - | -2,169 | -3,021 | - |
| Income tax expense (benefit) | - | 4 | - | - |
| Net loss | -3,200 | -2,187 | -3,021 | -2,145 |
| Earnings per share, basic and diluted | 0.07 | 0.055 | 0.08 | 0.06 |
| Earnings per share, diluted | 0.07 | 0.055 | 0.08 | 0.06 |
| Weighted average number of shares outstanding, basic and diluted | 47,089,814 | -18,542,296.5 | 37,644,612 | 37,090,160 |
| Weighted average number of shares outstanding, diluted | 47,089,814 | -18,542,296.5 | 37,644,612 | 37,090,160 |
Entera Bio Ltd. (ENTX)
Entera Bio Ltd. (ENTX)